Samsung Biologics said Tuesday it will participate in Interphex Week Tokyo 2025, Asia’s largest biopharmaceutical business-to-business convention, taking place July 9-11  at Tokyo Big Sight in Japan.

Organized by global exhibition leader RX (Reed Exhibitions), Interphex Week Tokyo is in its 27th year and is recognized as a key platform for forming partnerships in biopharmaceutical manufacturing and R&D. This year’s event is expected to draw over 900 companies from 25 countries and more than 34,000 participants.

Samsung Biologics, which also participated last year, will operate its own booth to meet with existing clients and actively pursue new customer leads, with a particular focus on securing contracts from top 40 global pharmaceutical firms.

Earlier this year, the company opened a new sales office in Tokyo, following its U.S. office launch, to strengthen its footprint in the Asia-Pacific market.

On the opening day of the convention, Marc Studer, Head of ADC/mRNA Operations at Samsung Biologics, will deliver a presentation titled “Navigating ADC Complexity: Ensuring safety, quality, and speed through a strategic CDMO partnership.” The session will highlight the company’s capabilities in the antibody-drug conjugate (ADC) contract development and manufacturing (CDMO) space.

Samsung Biologics began operation of its dedicated ADC manufacturing facility in March of this year, officially launching its ADC CDMO business. The plant includes a 500-liter conjugation reactor and a purification line, enabling the production of ADC drug substances (DS). The company plans to complete drug product (DP) manufacturing capabilities by 2027, aiming to offer a full end-to-end ADC CDMO service.

The Tokyo convention is part of a broader global outreach effort by Samsung Biologics in 2025. The company has already engaged clients at major industry events including the J.P. Morgan Healthcare Conference in January, DCAT Week in March, and BIO International Convention in Boston last month. Samsung Biologics is also scheduled to attend BioJapan 2025 and CPHI Worldwide later this year to further expand engagement with global and prospective partners.